<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02331511</url>
  </required_header>
  <id_info>
    <org_study_id>CVRC100</org_study_id>
    <nct_id>NCT02331511</nct_id>
  </id_info>
  <brief_title>Prevention of Venous Obstruction After Implantation of Cardiac Pacemaker and Defibrillator</brief_title>
  <official_title>Effect of Aspirin and Clopidogrel in Prevention of Venous Obstruction After Implantation of Cardiac Pacemaker and Defibrillator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Aspirin or Clopidogrel are effective in the
      prevention of venous obstruction after implantation of cardiac pacemaker or defibrillator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are growing numbers of endocardial permanent pacemakers (PPM) and implantable
      cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT) device.
      Asymptomatic obstruction of the access vein reported to have a high incidence (30-50%) in
      some studies. This complication can cause some difficulties in follow up procedures such as
      device upgrading. The purpose of this study is to determine whether Aspirin or Clopidogrel
      are effective in the prevention of venous obstruction after implantation of cardiac pacemaker
      or defibrillator.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venus obstruction(axillary or subclavian vein) more than 50%(measure by venography)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>major bleeding</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A composite of death of any cause, myocardial infarction, or cerebrovascular accident.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Complication of Cardiac Defibrillator</condition>
  <condition>Disorder of Cardiac Pacemaker System</condition>
  <condition>Venous Occlusion</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No antiplatelet drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 80 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo administration for 3 months after device(PPM,ICD,CRT) implantation</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo 1 tablet daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 80 mg daily</intervention_name>
    <description>Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75 mg daily</intervention_name>
    <description>Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Clopidogrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who referred for first implantation of pacemaker, implantable cardiac
             defibrillator, or cardiac re synchronization therapy device

        Exclusion Criteria:

          -  history of malignancy

          -  history of coagulopathy or platelet disorder

          -  history of venous thromboembolism

          -  history of gastrointestinal hemorrhage or active gastroduodenal ulcer in past 6 months

          -  history of chronic kidney disorder or serum creatinine more than 1.5 mg/dl

          -  patients who are on anticoagulant or other antithrombotic drugs or who must be on dual
             antiplatelet therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morteza Saafi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Ali Akbarzadeh, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad Ali Akbarzadeh, M.D.</last_name>
    <phone>+98 917 317 1001</phone>
    <email>akbarzadehali@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shahid ModaressHospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Ali Akbarzadeh, M.D</last_name>
      <phone>(+98)9173171001</phone>
      <email>akbarzadehali@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mohammad Ali Akbarzadeh, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2015</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mohammad Ali Akbarzadeh</investigator_full_name>
    <investigator_title>Assistant proffesor of shahid beheshti university of medical sciences</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

